Saturday, September 20, 2014 8:10:20 AM
From: Gerald E. Commissiong, President & CEO
With that being said, we recognize that it is not optimal to up list from a position of weakness, and therefore we will only consider an up list from a position of strength while the Company is making good progress in the market. We believe the milestones we’ve outlined above – for the end of 2014 alone – will put us in that position. However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value. - See more at: http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/fundamental-milestones-ahead-listing-strength/#sthash.Z4x7623N.dpuf
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM